Elizabeth Anderson
Stock Analyst at Evercore ISI Group
(2.12)
# 2,823
Out of 4,906 analysts
119
Total ratings
42.86%
Success rate
-5.01%
Average return
Main Sectors:
Stocks Rated by Elizabeth Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TDOC Teladoc Health | Maintains: In-Line | $7 → $8 | $8.33 | -3.96% | 4 | Jul 9, 2025 | |
| PRVA Privia Health Group | Maintains: Outperform | $30 → $28 | $20.16 | +38.89% | 4 | Jul 9, 2025 | |
| NVST Envista Holdings | Maintains: Outperform | $19 → $23 | $19.47 | +18.13% | 4 | Jul 9, 2025 | |
| MCK McKesson | Maintains: Outperform | $760 → $800 | $711.21 | +12.48% | 6 | Jul 9, 2025 | |
| LH Labcorp Holdings | Maintains: Outperform | $260 → $285 | $243.04 | +17.26% | 5 | Jul 9, 2025 | |
| IQV IQVIA Holdings | Maintains: Outperform | $170 → $180 | $158.96 | +13.24% | 6 | Jul 9, 2025 | |
| HCAT Health Catalyst | Maintains: In-Line | $5 → $4 | $3.87 | +3.36% | 7 | Jul 9, 2025 | |
| FTRE Fortrea Holdings | Maintains: In-Line | $6 → $5 | $4.66 | +7.30% | 8 | Jul 9, 2025 | |
| AGL agilon health | Maintains: In-Line | $5 → $3 | $2.14 | +40.19% | 5 | Jul 9, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $50 → $70 | $60.25 | +16.18% | 8 | Jul 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $175 → $180 | $158.58 | +13.51% | 8 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $200 | $189.02 | +5.81% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $175 → $180 | $166.45 | +8.14% | 3 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $65 | $61.64 | +5.45% | 6 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $9 → $12 | $11.52 | +4.17% | 13 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $20 | $15.64 | +27.92% | 7 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $36 | $36.97 | -2.62% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: In-Line | $68 → $26 | $5.63 | +366.25% | 3 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $35 → $15 | $3.73 | +302.14% | 3 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 | $2.09 | +426.32% | 2 | Jan 4, 2022 |
Teladoc Health
Jul 9, 2025
Maintains: In-Line
Price Target: $7 → $8
Current: $8.33
Upside: -3.96%
Privia Health Group
Jul 9, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $20.16
Upside: +38.89%
Envista Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $19 → $23
Current: $19.47
Upside: +18.13%
McKesson
Jul 9, 2025
Maintains: Outperform
Price Target: $760 → $800
Current: $711.21
Upside: +12.48%
Labcorp Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $260 → $285
Current: $243.04
Upside: +17.26%
IQVIA Holdings
Jul 9, 2025
Maintains: Outperform
Price Target: $170 → $180
Current: $158.96
Upside: +13.24%
Health Catalyst
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $4
Current: $3.87
Upside: +3.36%
Fortrea Holdings
Jul 9, 2025
Maintains: In-Line
Price Target: $6 → $5
Current: $4.66
Upside: +7.30%
agilon health
Jul 9, 2025
Maintains: In-Line
Price Target: $5 → $3
Current: $2.14
Upside: +40.19%
Doximity
Jul 9, 2025
Upgrades: Outperform
Price Target: $50 → $70
Current: $60.25
Upside: +16.18%
Jun 12, 2025
Maintains: Outperform
Price Target: $175 → $180
Current: $158.58
Upside: +13.51%
May 1, 2025
Maintains: Outperform
Price Target: $165 → $200
Current: $189.02
Upside: +5.81%
Apr 23, 2025
Maintains: In-Line
Price Target: $175 → $180
Current: $166.45
Upside: +8.14%
Jan 27, 2025
Maintains: Outperform
Price Target: $60 → $65
Current: $61.64
Upside: +5.45%
Jan 13, 2025
Maintains: In-Line
Price Target: $9 → $12
Current: $11.52
Upside: +4.17%
Jan 7, 2025
Downgrades: In-Line
Price Target: $20
Current: $15.64
Upside: +27.92%
Nov 7, 2024
Maintains: Outperform
Price Target: $32 → $36
Current: $36.97
Upside: -2.62%
Mar 16, 2022
Maintains: In-Line
Price Target: $68 → $26
Current: $5.63
Upside: +366.25%
Mar 2, 2022
Downgrades: In-Line
Price Target: $35 → $15
Current: $3.73
Upside: +302.14%
Jan 4, 2022
Downgrades: In-Line
Price Target: $11
Current: $2.09
Upside: +426.32%